Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate

Condition(s) targeted: Burn

Intervention: fenofibrate (Drug); placebo (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: The University of Texas, Galveston

Official(s) and/or principal investigator(s):
David Herndon, MD, Principal Investigator, Affiliation: University of Texas Medical Branch, Galveston

Overall contact:
David N Herndon, MD, Phone: 409-770-6733, Email: dherndon@utmb.edu

Major burn injury causes significant insulin resistance on glucose and protein metabolism that persists for up to 6 months after the acute injury

This project proposes to answer the following questions:

1. Will fenofibrate given to burn patients with insulin resistance restore their insulin sensitivity?

2. What is the relationship between mitochondrial dysfunction in muscle tissue as the causative mechanism of burn related insulin resistance?

3. To what extent will the restored insulin sensitivity affect glucose and protein metabolism in muscle, regenerating wounds and the liver, i. e. ameliorate burn related hyperglycemia and protein catabolism?

Official title: The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Insulin sensitivity on glucose and protein metabolism

Secondary outcome:

Systemic glucose homeostasis

Muscle protein balance

Wound protein balance

Detailed description: The following specific hypotheses will be investigated:

1. Following severe burn injury in human patients the mitochondrial fat oxidation capacity is decreased in muscle. This is associated with a corresponding progression in the severity of the resistance to the action of insulin on glucose disposal and protein synthesis and breakdown in muscle, regenerating wound and liver.

2. Fatty acids, or their active intracellular products (e. g., DAG, acyl-CoA, or acylcarnitine), are the direct inhibitors of insulin action, rather than tissue TG itself. In other words, impaired mitochondrial fatty acid oxidation is the mechanism that causes altered lipid metabolism that ultimately contributes to insulin resistance.

3. Accumulation of active fatty acid products, such as DAG, acyl-CoA, or acylcarnitine esters in muscle cells is due to the rate of uptake of plasma FFA exceeding the rate of oxidation within muscle due principally to a reduced capacity of mitochondria to oxidize fatty acids.

4. Decreased insulin sensitivity in muscle is related to impaired insulin signaling. This will be reflected by increased activity of protein kinase C (PKC). Because PKC is thought to exert its regulatory effect primarily on either tyrosine kinase activity on the insulin receptor or downstream kinase insulin receptor substrate (IRS) phosphorylation, these elements of the insulin signaling cascade will be decreased. In turn, elements of insulin signaling related to the response of muscle glucose (PI3 kinase) and protein (P70S6k) metabolism will be reduced. We propose that increased tissue PKC activity will be associated with increased tissue concentration of DAG, acyl-CoA, or acylcarnitine.

5. Treatment of patients with the peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate will improve mitochondrial capacity to oxidize fatty acids.

6. Insulin sensitivity in muscle, skin and liver in terms of both glucose and protein metabolism will be improved by fenofibrate treatment.

Minimum age: 7 Years. Maximum age: 20 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients > 7 years old with burns covering 40% or more of body surface who are

admitted to the Shriners Hospital for Children, Galveston, TX

Exclusion Criteria:

- Abnormal liver and kidney function,

- Pregnancy,

- Diabetes mellitus,

David N Herndon, MD, Phone: 409-770-6733, Email: dherndon@utmb.edu

Shriners Hospital for Children, Galveston, Texas 77550, United States; Recruiting
Celeste C Finnerty, PhD, Phone: 409-770-6567, Email: ccfinner@utmb.edu
David N Herndon, MD, Principal Investigator

Starting date: August 2008
Last updated: June 21, 2011